Published on September 24, 2009 at 4:58 AM
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published a new report about CEL-SCI Corporation's (NYSE Amex: CVM) new H1N1 flu drug candidate.
Hype versus substance. Perception versus reality. During the past week, there has been much debate regarding the work being done by CEL-SCI in the pandemic influenza space, but previously published data may help shed new light on the L.E.A.P.S platform which is being used to develop the treatment.
Are there applications for CEL-SCI's work beyond the scope and urgency of the current pandemic that may open up other lucrative markets?
The new article can be read in their entirety at BioMedReports.Com:
http://biomedreports.com/component/content/article/56-top-leading-news/10621-intriguing-revelations-deciphering-cel-scis-h1n1-flu-play.html
SOURCE: BiomedReports.Com